These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38756783)

  • 41. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y
    J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus-specific memory T cells in adolescents.
    Zhao XJ; Liu XL; Gu HJ; Liu T; Li DY; Zhang S; Wu J; Du KG; Tian S; Chen JJ; Xu Q; Lv CL; Jiang BG; Wang H; Kou ZQ; Wang GL; Fang LQ
    J Med Virol; 2024 Aug; 96(8):e29873. PubMed ID: 39165041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
    Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
    J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 cellular and humoral responses in vaccine-naive individuals during the first two waves of COVID-19 infections in the southern region of The Netherlands: a cross-sectional population-based study.
    Hanssen DAT; Arts K; Nix WHV; Sweelssen NNB; Welbers TTJ; de Theije C; Wieten L; Pagen DME; Brinkhues S; Penders J; Dukers-Muijrers NHTM; Hoebe CJPA; Savelkoul PHM; van Loo IHM
    Microbiol Spectr; 2024 Jun; 12(6):e0012624. PubMed ID: 38686954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
    Chang TY; Li CJ; Chao TL; Chang SY; Chang SC
    Appl Microbiol Biotechnol; 2024 Oct; 108(1):486. PubMed ID: 39412657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A longitudinal study on SARS-CoV-2 seroconversion, reinfection and neutralisation spanning several variant waves and vaccination campaigns, Heinsberg, Germany, April 2020 to November 2022.
    Schulte B; Richter E; Büning A; Baum M; Breuer A; Zorn J; König J; Geiger M; Eschbach-Bludau M; Heuser J; Zölzer D; Korencak M; Hollstein R; Beins E; Emmert D; Aldabbagh S; Eis-Hübinger AM; Streeck H
    Euro Surveill; 2024 Jun; 29(26):. PubMed ID: 38940003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination.
    Gravenstein S; DeVone F; Oyebanji OA; Abul Y; Cao Y; Chan PA; Halladay CW; Rudolph JL; Nugent C; Bosch J; King CL; Wilson BM; Balazs AB; White EM; Canaday DH; McConeghy KW
    EBioMedicine; 2024 Jul; 105():105180. PubMed ID: 38861869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    Inizan C; Courtot A; Sturmach C; Griffon AF; Biron A; Bruel T; Enouf V; Demaneuf T; Munier S; Schwartz O; Gourinat AC; Médevielle G; Jouan M; van der Werf S; Madec Y; Albert-Dunais V; Dupont-Rouzeyrol M
    PLoS Med; 2024 Sep; 21(9):e1004397. PubMed ID: 39325828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific immunological characteristics and risk factor of XBB variants re-infection in nasopharyngeal carcinoma patients after BA.5 infection.
    Lei Y; Xu N; Niu C; Chen L; Yu P; Yan S; Wang F; Mai X; Deng M; Mai W; Zeng J; Zhang L; Bo H; Xiong X; Chen H; Ji T
    Virology; 2024 Sep; 597():110142. PubMed ID: 38959723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.
    Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC
    Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Chen C; Zhou X; Gao X; Pan R; He Q; Guo X; Yu S; Wang N; Zhao Q; Wang M; Xu Y; Han X
    Int J Cancer; 2024 Oct; 155(8):1409-1421. PubMed ID: 38837354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.